Drug Delivery: Surveying the Global Competitive Landscape

Products

Full Paper

Full Paper

Price: £595.00
Description: This 634 page report provides a detailed analysis of drug delivery speciliasts leading the field, technology and drug profiles and market trends.



Research Report Overview

Published Date: 31/12/2010
Category: Drug Delivery & Devices

Research Report Decription

pdf icon

Sample Pages:

Click here (PDF)

The importance of drug delivery technology grows ever more acute, commercial and industry interest is continuing to build. The benefits to patients can be seen in improved medical outcomes, while the pharmaceutical industry is able to extend patent protection through novel delivery regimes, bringing new therapies to the market that would, previously, have been impossible to administer.

This new, richly-detailed report provides the most comprehensive review of the sector and examines the competitive drug delivery landscape with analysis of 114 key companies. The company landscape is always changing: some have been bought by the big boys and aspiring developers, whilst others have just run out of money and gone to the wall. Slowly but surely the private equity groups - most of whom have been in relative hibernation for the past couple of years - are gradually returning to the fold and supporting financing rounds.

Key Questions Answered:

This report provides key insights for you to...

  • Identify exciting development companies with novel drug delivery technologies. 
  • Easily find out who your competitors are working with and on what.
  • Profile the leading drug delivery companies as they battle for supremacy.
  • Understand the trends which are affecting the sector

Companies Mentioned:

3M DDS, Abraxis BioScience, Access Pharmaceuticals, Alkermes , Apricus Biosciences, Baxa Corporation, Baxter International , BioDelivery Sciences International, Camurus AB, CareFusion, Cell Therapeutics, Cephalon, Cipher  Pharmaceuticals, Columbia Laboratories , Consort Medical, CyDex Pharmaceuticals, Debiopharm, DUSA Pharmaceuticals, Echo Therapeutics, Elan, Elite Pharmaceuticals , EGEN  , Endo Pharmaceuticals, Endocyte, Enzon , Eurand, Flamel Technologies , Gilead Sciences, Hospira, Ikano Therapeutics , Intercell ,KV Pharmaceutical, Labopharm  ,Lavipharm Group, Light Sciences Oncology, MannKind Corporation, Marina Biotech,  MaxCyte, MedImmune  ,Milestone Scientific, Moog Medical Devices, Nanobiotix, NanoMaterials Technology, NanoCarrier, Nektar Therapeutics, Noven Pharmaceuticals , Otsuka Holdings, Photocure ASA, PolyTherics, pSivida, QLT, Raptor Pharmaceuticals,  Retractable Technologies,  Savara Pharmaceuticals, Scolr Pharma, Seattle Genetics, SkyePharma PLC, Urigen Pharmaceuticals ,Valeant Pharmaceuticals , Vical Vivus, Zogenix, Zosano Pharma

Paper Highlights:

This report provides you with key data for each featured company...

  • Company Overview & Technology Focus
  • Key Personnel
  • Competition & Competing Products
  • Key Milestones
  • Products/Technologies
  • R&D & Research Strategy
  • Key Agreements & Alliances
  • Financial Data (where available)
  • Comprehensive Contact Details

The ability to readily assess the companies involved, research areas of interest, products being developed, strategic collaborations and performance are key to understanding this market. In 630+ information-packed pages, this new report Drug Delivery: Surveying the global competitive landscape (published December 2010) evaluates companies large and small from multinationals to specialist development and technology organisations. All major technology areas such as Controlled release, Nucleic acid, Nano-enabled and Targeted delivery are covered.